GeoVax Labs, Inc. has announced its second quarter 2025 financial results alongside significant advancements in its clinical-stage biotechnology pipeline, focusing on vaccines and immunotherapies for infectious diseases and cancer. The company's GEO-MVA vaccine received favorable European regulatory guidance, streamlining its development pathway for the prevention of Mpox and smallpox, with a Phase 3 trial expected to commence in the latter half of 2026. This development is particularly timely, given the World Health Organization's recent declaration of Mpox as a public health emergency of international concern.
Additionally, GeoVax's GEO-CM04S1 vaccine demonstrated superior immune responses in patients with Chronic Lymphocytic Leukemia (CLL), as presented at the European Hematology Association 2025 Conference. The vaccine's ability to elicit significant SARS-CoV-2 Nucleocapsid-specific IgG and T cell responses, where an authorized mRNA vaccine failed, underscores its potential in addressing unmet medical needs in immunocompromised populations.
The company also highlighted the progress of Gedeptin®, a gene-directed prodrug therapy for solid tumors, which showed promising safety and efficacy in clinical trials presented at the American Association for Cancer Research Annual Meeting. With an estimated global market potential exceeding $15 billion, Gedeptin® represents a significant advancement in oncology treatment options.
GeoVax's financial results for the second quarter of 2025 reflect a net loss of $5,369,783, or $0.35 per share, with research and development expenses primarily driven by program-specific costs associated with its vaccine candidates. Despite these losses, the company's advancements in its pipeline and the potential market impact of its products underscore its commitment to addressing critical health challenges worldwide.
